Hyperoxia exaggerates bacterial dissemination and lethality in Pseudomonas aeruginosa pneumonia

Pulmonary Pharmacology and Therapeutics

Volumn 22, Issue 4, 2009, Pages 333-339

  Kikuchi, Yoshiaki ^a,b   Tateda, Kazuhiro ^a   Fuse, Etsu T ^a   Matsumoto, Tetsuya ^c   Gotoh, Naomasa ^d   Fukushima, Jun ^e   Takizawa, Hajime ^f   Nagase, Takahide ^b   Standiford, Theodore J ^g   Yamaguchi, Keizo ^a  

^a TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c TOKYO MEDICAL UNIVERSITY   (Japan)

^d KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^e AKITA PREFECTURAL UNIVERSITY   (Japan)

^f TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Hyperoxia; Macrolide; Pseudomonas aeruginosa; Ventilator associated pneumonia

Indexed keywords

AZITHROMYCIN; CASPASE 3; CLARITHROMYCIN; DNA FRAGMENT; ERYTHROMYCIN; JOSAMYCIN; METALLOPROTEINASE; MIDECAMYCIN; OLEANDOMYCIN; ROKITAMYCIN; TELITHROMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL COUNT; BACTERIAL PNEUMONIA; BACTERIUM CULTURE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; GENE DISRUPTION; HUMAN; HUMAN CELL; HYPEROXIA; LETHALITY; LUNG ALVEOLUS EPITHELIUM; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SUPERNATANT; SURVIVAL; TREATMENT RESPONSE;

ANIMALS; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CASPASE 3; CELL LINE; CELL SURVIVAL; FEMALE; GENE DELETION; HISTONES; HUMANS; HYPEROXIA; LIVER; LUNG; MACROLIDES; MICE; MICE, INBRED BALB C; OXYGEN; PNEUMONIA, BACTERIAL; PROTEASE INHIBITORS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; VIRULENCE FACTORS;

EID: 67349113813     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2008.12.021     Document Type: Article

References (30)

1. Waxman A.B., Einarsson O., Seres T., Knickelbein R.G., Warshaw J.B., Johnston R., et al. Targeted lung expression of interleukin-11 enhances murine tolerance of 100% oxygen and diminishes hyperoxia-induced DNA fragmentation. J Clin Invest 101 (1998) 1970-1982
2. Barazzone C., and White C.W. Mechanisms of cell injury and death in hyperoxia: role of cytokines and Bcl-2 family proteins. Am J Respir Cell Mol Biol 22 (2000) 517-519
3. Tateda K., Deng J.C., Moore T.A., Newstead M.W., Paine III R., Kobayashi N., et al. Hyperoxia mediates acute lung injury and increased lethality in murine Legionella pneumonia: the role of apoptosis. J Immunol 170 (2003) 4209-4216
4. Chastre J., and Fagon J.Y. Ventilator-associated pneumonia. Am J Respir Crit Care Med 165 (2002) 867-903
5. Richards M.J., Edwards J.R., Culver D.H., and Gaynes R.P. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med 27 (1999) 887-892
6. Combes A., Luyt C.E., and Trouillet J.L. Impact of antibiotic-resistant bacteria on the outcome of ventilator-associated pneumonia. Semin Respir Crit Care Med 27 (2006) 23-28
7. Shaw M.J. Ventilator-associated pneumonia. Curr Opin Pulm Med 11 (2005) 236-241
8. Sadikot R.T., Blackwell T.S., Christman J.W., and Prince A.S. Pathogen-host interactions in Pseudomonas aeruginosa pneumonia. Am J Respir Crit Care Med 171 (2005) 1209-1223
9. Kudoh S., Uetake T., Hagiwara K., Hirayama M., Hus L.H., Kimura H., et al. Clinical effects of low-dose long-term erythromycin chemotherapy on diffuse panbronchiolitis. Nihon Kyobu Shikkan Gakkai Zasshi 25 (1987) 632-642
10. Kudoh S., Azuma A., Yamamoto M., Izumi T., and Ando M. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med 157 (1998) 1829-1832
11. Jaffe A., Francis J., Rosenthal M., and Bush A. Long-term azithromycin may improve lung function in children with cystic fibrosis. Lancet 351 (1998) 420
12. Equi A., Balfour-Lynn I.M., Bush A., and Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 360 (2002) 978-984
13. Saiman L., Marshall B.C., Mayer-Hamblett N., Burns J.L., Quittner A.L., Cibene D.A., et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 290 (2003) 1749-1756
14. Kita E., Sawaki M., Oku D., Hamuro A., Mikasa K., Konishi M., et al. Suppression of virulence factors of Pseudomonas aeruginosa by erythromycin. J Antimicrob Chemother 27 (1991) 273-284
15. Nguyen T., Louie S.G., Beringer P.M., and Gill M.A. Potential role of macrolide antibiotics in the management of cystic fibrosis lung disease. Curr Opin Pulm Med 8 (2002) 521-528
16. Amsden G.W. Anti-inflammatory effects of macrolides - an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?. J Antimicrob Chemother 55 (2005) 10-21
17. Sakata K., Yajima H., Tanaka K., Sakamoto Y., Yamamoto K., Yoshida A., et al. Erythromycin inhibits the production of elastase by Pseudomonas aeruginosa without affecting its proliferation in vitro. Am Rev Respir Dis 148 (1993) 1061-1065
18. Tateda K., Standiford T.J., Pechere J.C., and Yamaguchi K. Regulatory effects of macrolides on bacterial virulence: potential role as quorum-sensing inhibitors. Curr Pharm Des 10 (2004) 3055-3065
19. Gotoh N., Tsujimoto H., Tsuda M., Okamoto K., Nomura A., Wada T., et al. Characterization of the MexC-MexD-OprJ multidrug efflux system in DeltamexA-mexB-oprM mutants of Pseudomonas aeruginosa. Antimicrob Agents Chemother 42 (1998) 1938-1943
20. Kuwayama H., Obara S., Morio T., Katoh M., Urushihara H., and Tanaka Y. PCR-mediated generation of a gene disruption construct without the use of DNA ligase and plasmid vectors. Nucleic Acids Res 30 (2002) E2
21. Shigematsu T., Fukushima J., Oyama M., Tsuda M., Kawamoto S., and Okuda K. Iron-mediated regulation of alkaline proteinase production in Pseudomonas aeruginosa. Microbiol Immunol 45 (2001) 579-590
22. Tateda K., Takashima K., Miyazaki H., Matsumoto T., Hatori T., and Yamaguchi K. Noncompromised penicillin-resistant pneumococcal pneumonia CBA/J mouse model and comparative efficacies of antibiotics in this model. Antimicrob Agents Chemother 40 (1996) 1520-1525
23. Hirakata Y., Kaku M., Mizukane R., Ishida K., Furuya N., Matsumoto T., et al. Potential effects of erythromycin on host defense systems and virulence of Pseudomonas aeruginosa. Antimicrob Agents Chemother 36 (1992) 1922-1927
24. Tateda K., Comte R., Pechere J.C., Köhler T., Yamaguchi K., and Van Delden C. Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa. Antimicrob Agents Chemother 45 (2001) 1930-1933
25. Kipnis E., Sawa T., and Wiener-Kronish J. Targeting mechanisms of Pseudomonas aeruginosa pathogenesis. Med Mal Infect 36 (2006) 78-91
26. Azghani A.O., Connelly J.C., Peterson B.T., Gray L.D., Collins M.L., and Johnson A.R. Effects of Pseudomonas aeruginosa elastase on alveolar epithelial permeability in guinea pigs. Infect Immun 58 (1990) 433-438
27. Azghani A.O., Gray L.D., and Johnson A.R. A bacterial protease perturbs the paracellular barrier function of transporting epithelial monolayers in culture. Infect Immun 61 (1993) 2681-2686
28. Marquart M.E., Caballero A.R., Chomnawang M., Thibodeaux B.A., Twining S.S., and O'Callaghan R.J. Identification of a novel secreted protease from Pseudomonas aeruginosa that causes corneal erosions. Invest Ophthalmol Vis Sci 46 (2005) 3761-3768
29. Azghani A.O. Pseudomonas aeruginosa and epithelial permeability: role of virulence factors elastase and exotoxin A. Am J Respir Cell Mol Biol 15 (1996) 132-140
30. Giamarellos-Bourboulis E.J., Pechère J.C., Routsi C., Plachouras D., Kollias S., Raftogiannis M., et al. Effect of clarithromycin in patients with sepsis and ventilator-associated pneumonia. Clin Infect Dis 46 (2008) 1157-1164